Impact of the Localization of the Primary Tumor and RAS/BRAF Mutational Status on Maintenance Strategies After First-line Oxaliplatin, Fluoropyrimidine, and Bevacizumab in Metastatic Colorectal Cancer: Results From the AIO 0207 Trial

Noepel-Duennebacke Stefanie; Arnold Dirk; Hertel Jan; Tannapfel Andrea; Hinke Axel; Hegewisch-Becker Susanna; Reinacher-Schick Anke

首页> 外文期刊>Clinical colorectal cancer >Impact of the Localization of the Primary Tumor and RAS/BRAF Mutational Status on Maintenance Strategies After First-line Oxaliplatin, Fluoropyrimidine, and Bevacizumab in Metastatic Colorectal Cancer: Results From the AIO 0207 Trial

【24h】

Impact of the Localization of the Primary Tumor and RAS/BRAF Mutational Status on Maintenance Strategies After First-line Oxaliplatin, Fluoropyrimidine, and Bevacizumab in Metastatic Colorectal Cancer: Results From the AIO 0207 Trial

机译：原发性肿瘤和RAS / BRAF突变状况定位对一线奥沙利铂，氟嘧啶和转移性结直肠癌贝伐单抗的维持策略的影响：来自AIO 0207试验的结果

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

The retrospective analysis of the AIO (Arbeitsgemeinschaft Internistische Onkologie) 0207 trial failed to show any impact from localization of the primary tumor or from any standard molecular factor (RAS and BRAF) on the prediction of a benefit of different maintenance treatment strategy in patients with metastastic colorectal cancer after induction chemotherapy with oxaliplatin, fluoropyrimidine, and bevacizumab.

机译：AIO（Arbeitsgemeinschaft Internistische Onkologie）的回顾性分析0207试验未能显示原发性肿瘤的定位或任何标准分子因子（RAS和BRAF）的任何影响，以预测转移患者不同维持治疗策略的益处用奥沙利铂，氟嘧啶和Bevacizumab诱导化疗后结直肠癌。

著录项

来源
《Clinical colorectal cancer》 |2018年第4期|共7页
作者
Noepel-Duennebacke Stefanie; Arnold Dirk; Hertel Jan; Tannapfel Andrea; Hinke Axel; Hegewisch-Becker Susanna; Reinacher-Schick Anke;
展开▼
作者单位

Ruhr Univ St Josef Hosp Bochum Div Hematol Oncol &

Palliat Care Bochum Germany;

Asklepiostumorzentrum Hamburg Dept Oncol &

Hematol Palliat Care AK Altona Hamburg Germany;

Ruhr Univ St Josef Hosp Bochum Div Hematol Oncol &

Palliat Care Bochum Germany;

Ruhr Univ Inst Pathol Bochum Germany;

CCRC Dusseldorf Germany;

HOPE Practice Oncol Hamburg Germany;

Ruhr Univ St Josef Hosp Bochum Div Hematol Oncol &

Palliat Care Bochum Germany;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
Bevacizumab; BRAF; Maintenance; Metastatic colorectal cancer; Sidedness;

机译：Bevacizumab;BRAF;维护;转移性结直肠癌;相似;

相似文献

外文文献
中文文献
专利

1. CMAB009联合伊立替康或伊立替康单药二线治疗氟嘧啶和奥沙利铂治疗失败的KRAS野生型转移性结直肠癌患者的研究:一项前瞻性、开放、随机、Ⅲ期试验 [J] . 石远凯, 白丽, 张沂平, 癌症（英文版） . 2020,第007期
2. Impact of the Localization of the Primary Tumor and RAS/BRAF Mutational Status on Maintenance Strategies After First-line Oxaliplatin, Fluoropyrimidine, and Bevacizumab in Metastatic Colorectal Cancer: Results From the AIO 0207 Trial [J] . Noepel-Duennebacke Stefanie, Arnold Dirk, Hertel Jan, Clinical colorectal cancer . 2018,第4期

机译：原发性肿瘤和RAS / BRAF突变状况定位对一线奥沙利铂，氟嘧啶和转移性结直肠癌贝伐单抗的维持策略的影响：来自AIO 0207试验的结果
3. Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial [J] . Hegewisch-Becker Susanna, Noepel-Duennebacke Stefanie, Hinke Axel, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2018,第期

机译：含有奥沙利铂和贝伐单抗的一线方案治疗原发性肿瘤位置和RAS / BRAF突变状态的影响：来自AIO KRK0207一线和维持治疗试验的预后因素
4. Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial [J] . Hegewisch-Becker Susanna, Noepel-Duennebacke Stefanie, Hinke Axel, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2018,第期

机译：含有奥沙利铂和贝伐单抗的一线方案治疗原发性肿瘤位置和RAS / BRAF突变状态的影响：来自AIO KRK0207一线和维持治疗试验的预后因素
5. Isolation of Circulating Tumor Cells from Patients with Metastatic Colorectal Cancer Using Label-Free Microfluidic Technology for Enumeration and Detection of KRAS, BRAF, PIK3CA Mutation [C] . Haiyan Emily Liu, Evelyn Kidess-Sigal, Melanie Triboulet, International Molecular Medicine Tri-Conference. . 2016

机译：使用无标记微流体技术分离转移性结肠直肠癌患者的循环肿瘤细胞进行募准和检测KRA，BRAF，PIK3CA突变
6. Does anti-p53 antibody status predict for clinical outcomes in metastatic colorectal cancer patients treated with fluoropyrimidine oxaliplatin plus bevacizumab as first-line chemotherapy? [O] . Hiroki Osumi, Eiji Shinozaki, Mitsukuni Suenaga, 2015

机译：抗p53抗体的状态是否可预测以氟嘧啶奥沙利铂和贝伐单抗作为一线化疗的转移性结直肠癌患者的临床结局？
7. Maintenance strategy with fluoropyrimidines (FP) plus bevacizumab (Bev), Bev alone, or no treatment, following a standard combination of FP, oxaliplatin (Ox), and Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC) : results of the AIO KRK 0207 phase III\ua0study [O] . Hegewisch-Becker, Susanna, Arnold, Dirk, Lerchenmufcller, Christian, 2014

机译：标准方法联合使用FP，奥沙利铂（Ox）和Bev作为转移性结直肠癌（mCRC）患者的一线治疗后，采用氟嘧啶（FP）加贝伐单抗（Bev），单独或不进行治疗的维持策略AIO KRK 0207第III阶段\ ua0研究

Impact of the Localization of the Primary Tumor and RAS/BRAF Mutational Status on Maintenance Strategies After First-line Oxaliplatin, Fluoropyrimidine, and Bevacizumab in Metastatic Colorectal Cancer: Results From the AIO 0207 Trial

摘要

著录项

相似文献

相关主题

期刊订阅